Business

The recent approval by the FDA of Merck’s Enflonsia, a monoclonal antibody aimed at protecting infants from respiratory syncytial virus (RSV), marks a significant moment in both public health and pharmaceutical competition. However, it’s impossible not to question whether this monumental step is truly beneficial or simply another product designed to capitalize on a vulnerability
0 Comments
As air travel becomes more accessible, the experience of flying has simultaneously shifted into a dichotomy of lavishness and limitation. While airplane tickets have seen a decline in prices, the cost of comfort at the airport has risen to new heights. Recently, Capital One made headlines by imposing stricter regulations around access to its airport
0 Comments
In the face of economic turbulence, Lululemon Athletica has emerged with fiscal first-quarter earnings that exceeded Wall Street’s projections—albeit in the shadow of reduced full-year guidance. The results reflect not only the company’s robust performance but also the unpredictable landscape posed by global tariffs and fears of a contracting U.S. economy. CEO Calvin McDonald’s assertion
0 Comments
This summer, the luxurious Hamptons is grappling with a distinctly uninspiring rental market that’s seen a dramatic downturn. As brokers sift through an increasing number of unrented homes, it is becoming painfully clear that the upsurge in demand anticipated by many real estate experts will not manifest this season. Analysts have reported a staggering 30%
0 Comments